Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.63
- Piotroski Score 4.00
- Grade Buy
- Symbol (EYEG)
- Company EyeGate Pharmaceuticals, Inc.
- Price $37.09
- Changes Percentage (-0.26%)
- Change -$0.1
- Day Low $37.09
- Day High $37.19
- Year High $37.19
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
- Last Earnings 08/30/2024
- Ex-Dividend for 5/16 Dividend 09/03/2024
- Dividend Payable 09/06/2024
- Today N/A
- Next Earnings (Estimated) 11/08/2021
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.77
- Trailing P/E Ratio -19.94
- Forward P/E Ratio -19.94
- P/E Growth -19.94
- Net Income $-8,091,940
Income Statement
Quarterly
Annual
Latest News of EYEG
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The 6 best places to buy low-cost prescription eyeglasses for kids
CBS Essentials is a separate entity from CBS News editorial staff, earning commissions from product links. Find back-to-school deals on prescription eyewear for kids, with options under $100 from comp...
By CBS News | 1 month ago
